Bio-Rad has also expanded its anti-ipilimumab and anti-secukinumab portfolio to become the first provider of antibodies specific to the drug-target complex, allowing the detection of bound drug. HRP-labeled TrailBlazer antibodies are also now available for evolocumab.
“Bio-Rad’s leading portfolio of monoclonal anti-idiotypic antibodies offers researchers greater flexibility for the development of highly selective and highly sensitive bioanalytical assays,” said Dr John Cardone, marketing manager, Custom Antibodies, Life Science Group, Bio-Rad. “Our drug-target complex binders are unique to Bio-Rad, enabling researchers to detect drugs in the target-bound state, and all our anti-idiotypic antibodies are provided with in-depth data packages for reproducible results.”
These new anti-idiotypic antibodies are approved for in vitro research, for commercial in vitro testing services to support preclinical and clinical drug and biosimilar development, and patient monitoring.
To learn more about Bio-Rad’s anti-idiotypic antibodies, visit: www.bio-rad-antibodies.com/anti-idiotypic-antibody.html.
Digital issue: Please click here for more information